Comment on “Evaluating Biomarkers for Testosterone Replacement Efficacy in Testicular Cancer Survivors With Mild Leydig Cell Insufficiency”
Clinical Genitourinary Cancer · 2024
DOI: 10.1016/j.clgc.2024.102151 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical Genitourinary Cancer, 2024. Verfasst von Gokul Sudhakaran. Beteiligte Einrichtung: Center for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Thandalam, T…. Hauptthemen laut MEDLINE: Testosterone, Testicular Neoplasms, Leydig Cells, Hormone Replacement Therapy. Die Arbeit nennt 3 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Thandalam, Tamil Nadu, India. Electronic address: gokuls.smc@saveetha.com.
Zitieren
APA
Sudhakaran, G. (2024). Comment on “Evaluating Biomarkers for Testosterone Replacement Efficacy in Testicular Cancer Survivors With Mild Leydig Cell Insufficiency”. Clinical Genitourinary Cancer. https://doi.org/10.1016/j.clgc.2024.102151
Vancouver
Sudhakaran G. Comment on “Evaluating Biomarkers for Testosterone Replacement Efficacy in Testicular Cancer Survivors With Mild Leydig Cell Insufficiency”. Clinical Genitourinary Cancer. 2024. doi:10.1016/j.clgc.2024.102151
BibTeX
@article{Sudhakaran2024,
author = {Sudhakaran, Gokul},
title = {Comment on “Evaluating Biomarkers for Testosterone Replacement Efficacy in Testicular Cancer Survivors With Mild Leydig Cell Insufficiency”},
journal = {Clinical Genitourinary Cancer},
year = {2024},
doi = {10.1016/j.clgc.2024.102151}
}
EUVIMED